Email Updates

You are here

AVAC in the News

  • Buried within a 2009 New England Journal of Medicine article on an HIV vaccine regimen was a sentence that would change the face of HIV vaccine research for the next decade: "the modified intention-to-treat analysis showed a significant, though modest reduction in the rate of HIV-1 infection as compared with placebo."

    December 3, 2019
    MedPage Today
  • Much of the progress in fighting HIV/AIDS is thanks to treatments such as antiretroviral (ARV) drugs. Alongside those, however, are other innovations that have provided models for broader moves towards universal health coverage.

    November 28, 2019
    Financial Times
  • The New HIV and Vaccine Microbicides Advocacy Society (NHVMAS) Wednesday urged the Federal Ministry of Health to reduce the age of access for both Sexual Reproductive Health (SRH) and HIV testing services to 14 years. The civil society organisation, which made this known at a round table discussion in Abuja, in collaboration with AVAC and GADO Agency LTD Nigeria, also urged the government to integrate SRH education into the curriculum of schools.

    November 20, 2019
    The Nation
  • The US government routinely sues pharmaceutical companies for making false claims, bilking Medicare, illegal kickbacks, and sloppy manufacturing practices. But on 6 November, the US Department of Justice (DOJ) filed suit against Gilead Sciences Inc. of Foster City, California, for reasons that cannot easily fit on a bumper sticker.

    November 8, 2019
  • The Trump administration, on behalf of the Department of Health and Human Services (HHS), filed a patent infringement lawsuit against pharmaceutical manufacturer Gilead Sciences, seeking damages from infringement on HHS patents related to HIV prevention medications, the agency announced on Wednesday night.

    November 7, 2019
    MedPage Today
  • As expected, the FDA granted a pre-exposure prophylaxis (PrEP) indication to the HIV drug combination emtricitabine/tenofovir alafenamide (F/TAF, Descovy), to prevent infection in at-risk individuals except those who have receptive vaginal sex.

    October 3, 2019
    MedPage Today
  • Jonathan Van Ness is coming forward about the moment he discovered he was HIV-positive. The Queer Eye star talked about the news in an interview with NBC's TODAY on Tuesday and also chatted about its connection to his new memoir, Over The Top.

    September 24, 2019
    Daily Mail
  • Communities need to be involved in research — not just as participants, but also in shaping the research project, say AVAC and UNAIDS' Good Participatory Practices guidelines (GPP). But how are these guidelines implemented, and what is the outcome? Researchers shared their experiences at the International AIDS Society Conference in July.

    August 28, 2019
    The Body Pro
  • Among all the CAR-T commotion you may have missed it: An FDA panel on Wednesday recommended Gilead’s Descovy to block HIV transmission in men and transgender women, a step toward another PrEP finally coming to market (the sole medicine right now being Gilead’s Truvada). One potential snag — the advisory committee narrowly voted not to recommend the medicine, which is already approved to treat HIV, for women who are not transgender, also referred to as cisgender women.

    August 9, 2019
  • An FDA advisory panel overwhelmingly voted 16-2 to recommend Descovy, the fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF), as pre-exposure prophylaxis (PrEP) to reduce HIV acquisition in men who have sex with men (MSM) and transgender women. But murmurs echoed throughout the room as the FDA's Antimicrobial Drugs Advisory Committee split 8-10 on whether to recommend a PrEP indication for F/TAF in cisgender women.

    August 7, 2019
    MedPage Today